fampridine
E153840
Fampridine is a potassium channel blocker medication primarily used to improve walking in adults with multiple sclerosis.
All labels observed (3)
| Label | Occurrences |
|---|---|
| Ampyra | 3 |
| dalfampridine | 3 |
| fampridine canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T1351576 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: fampridine Context triple: [Fampyra, hasActiveIngredient, fampridine]
-
A.
Tecfidera
Tecfidera is an oral disease-modifying medication used to treat relapsing forms of multiple sclerosis by reducing inflammation and relapse frequency.
-
B.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
C.
riluzole
Riluzole is a neuroprotective medication that modestly prolongs survival and slows disease progression in people with amyotrophic lateral sclerosis (ALS).
-
D.
Spinraza
Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
-
E.
rivastigmine
Rivastigmine is a cholinesterase inhibitor medication used to manage symptoms of mild to moderate dementia, particularly in Alzheimer's and Parkinson's disease.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: fampridine Target entity description: Fampridine is a potassium channel blocker medication primarily used to improve walking in adults with multiple sclerosis.
-
A.
Tecfidera
Tecfidera is an oral disease-modifying medication used to treat relapsing forms of multiple sclerosis by reducing inflammation and relapse frequency.
-
B.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
C.
riluzole
Riluzole is a neuroprotective medication that modestly prolongs survival and slows disease progression in people with amyotrophic lateral sclerosis (ALS).
-
D.
Spinraza
Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
-
E.
rivastigmine
Rivastigmine is a cholinesterase inhibitor medication used to manage symptoms of mild to moderate dementia, particularly in Alzheimer's and Parkinson's disease.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
medication
ⓘ
potassium channel blocker ⓘ small molecule ⓘ |
| actsOn | central nervous system ⓘ |
| approvedBy |
U.S. Food and Drug Administration
ⓘ
linked to:
Food and Drug Administration
|
| approvedFor | improvement of walking in adults with multiple sclerosis ⓘ |
| belongsToPharmacologicalGroup | other nervous system drugs ⓘ |
| contraindicatedIn |
moderate or severe renal impairment
ⓘ
patients with history of seizures ⓘ |
| developedBy | Acorda Therapeutics ⓘ |
| discoveredAs | 4-aminopyridine derivative used as a research tool before clinical use ⓘ |
| hasAdverseEffect |
back pain
ⓘ
balance disorder ⓘ dizziness ⓘ headache ⓘ insomnia ⓘ nausea ⓘ paresthesia ⓘ seizures ⓘ urinary tract infection ⓘ |
| hasATCCode | N07XX07 ⓘ |
| hasBlackBoxWarning | risk of seizures ⓘ |
| hasBrandName |
Ampyra
ⓘ
linked to:
fampridine
Fampyra ⓘ |
| hasChemicalClass | pyridine derivative ⓘ |
| hasDosageForm | extended-release tablet ⓘ |
| hasDosingFrequency | typically twice daily for extended-release formulation ⓘ |
| hasEffect | increases walking speed in some patients with multiple sclerosis ⓘ |
| hasEliminationRoute | renal ⓘ |
| hasGenericName | fampridine ⓘ |
| hasHalfLife | approximately 5–6 hours in adults with normal renal function ⓘ |
| hasInternationalNonproprietaryName | fampridine ⓘ |
| hasMechanismOfAction |
blocks voltage-gated potassium channels
ⓘ
enhances conduction in demyelinated axons ⓘ |
| hasMolecularFormula | C5H6N2 ⓘ |
| hasPregnancyCategory | use only if potential benefit justifies potential risk ⓘ |
| hasRegulatoryStatus | prescription-only medicine ⓘ |
| hasRisk | increased seizure risk at higher than recommended doses ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasTargetPopulation | adults with multiple sclerosis ⓘ |
| hasTherapeuticArea | neurology ⓘ |
| hasUSAN |
dalfampridine
ⓘ
linked to:
fampridine
|
| indicatedFor |
multiple sclerosis
ⓘ
walking disability in multiple sclerosis ⓘ |
| metabolizedBy | kidney excretion largely unchanged ⓘ |
| notRecommendedFor | patients younger than 18 years ⓘ |
| usedFor | improvement of walking in adults with multiple sclerosis ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: fampridine Description of subject: Fampridine is a potassium channel blocker medication primarily used to improve walking in adults with multiple sclerosis.
Referenced by (8)
Full triples — surface form annotated when it differs from this entity's canonical label.
linked to: fampridine
linked to: fampridine
linked to: fampridine
linked to: fampridine
linked to: fampridine
subject linked to:
Acorda Therapeutics
linked to: fampridine